Phase III Clinical & Commercial cGMP Manufacturing Agreement Signed by Celtic Pharma and QSV Biologics, Ltd., for TransMID
QSV Biologics, Ltd (QSV) and Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) announced the signing of a cGMP manufacturing agreement for TransMID(TM). QSV will be responsible for cGMP manufacture of further phase III clinical trial material and longer term commercial manufacture in their licensed cGMP manufacturing facility. TransMID(TM) is being developed for the specific treatment of progressive and recurrent non-resectable glioblastoma multiforme, a particularly dangerous type of brain tumor where the average life expectancy is less than six months upon diagnosis.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.